Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 1, 2017

Study Completion Date

September 1, 2017

Conditions
Breast CancerMetastasis
Interventions
OTHER

Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)

Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.

Trial Locations (17)

13009

Institut Paoli Calmettes, Marseille

14000

Centre François Baclesse, Caen

21079

Centre Georges François Leclerc, Dijon

25030

Hôpital Jean Minjoz - CHU Besançon, Besançon

31052

Institut Claudius Regaud, Toulouse

33000

Institut Bergonié, Bordeaux

34000

Val d'Aurelle, Montpellier

38028

Institut Daniel Hollard, Grenoble

44805

Centre René Gauducheau, Saint-Herblain

51100

Institut Jean Godinot, Reims

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

67065

Centre Paul Strauss, Strasbourg

69373

Centre Léon Bérard, Lyon

75248

Institut Curie, Paris

87042

Hôpital Dupuytren, Limoges

94805

Institut Gustave Roussy, Villejuif

06000

Centre Antoine Lacassagne, Nice

All Listed Sponsors
collaborator

Centre de Recherche en Cancérologie de Lyon

UNKNOWN

lead

Centre Leon Berard

OTHER

NCT01460186 - Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter